Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer announced topline results from the Phase 3 SigVie-002 study for sigvotatug vedotin. The drug did not show a statistically significant improvement in overall survival compared to docetaxel in the overall patient population. However, a stronger trend for survival and progression-free survival appeared in patients who had received only one prior line of therapy.
What changed
Pfizer released topline Phase 3 results showing the drug failed to meet its primary endpoint for overall survival.
Live updates
-
Pfizer's Sigvotatug Vedotin Misses Primary Goal in Phase 3 Lung Cancer Trial
confidence 100%Pfizer announced topline results from the Phase 3 SigVie-002 study for sigvotatug vedotin. The drug did not show a statistically significant improvement in overall survival compared to docetaxel in the overall patient population. However, a stronger trend for survival and progression-free survival appeared in patients who had received only one prior line of therapy.
What's confirmed:
- The SigVie-002 study evaluated sigvotatug vedotin in adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer.
- Sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel in the overall population.
- Patients who received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival.
- The safety profile of sigvotatug vedotin was manageable and consistent with prior studies.
- Sigvotatug vedotin is an investigational, potential first-in-class integrin beta-6 directed antibody-drug conjugate.
Still unconfirmed:
- Pfizer's 43 billion dollar Seagen acquisition bet is souring further due to this failure.
- PFE stock is reacting to these mixed topline results.